Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets), after Enanta Pharmaceuticals filed a complaint citing patent infringement.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 September 2022 Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.
9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.